At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 27 enrolled
Drug / intervention
Biktarvy 50Mg-200Mg-25Mg Tablet +1 moredrug
Likely dose
Biktarvy 50Mg-200Mg-25Mg Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Implementation of Onsite, Rapid Antiretroviral Therapy (ART) Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program
In Brief
A Phase 4 clinical trial evaluating Biktarvy 50Mg-200Mg-25Mg Tablet and HIV care for Harm Reduction and 2 related conditions. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to see if providing HIV medicine right away at the IDEA Syringe Services Program will help the participant start and remain in HIV care, including having no detectable HIV in the participant's blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHarm Reduction, HIV Infections, Drug Use
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionDec 2023
TodayJul 2026
First PostedDec 2, 2020
Enrollment StartMar 4, 2021
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.6 years ago
Interventions
Biktarvy 50Mg-200Mg-25Mg Tabletdrug
Daily Biktarvy (50/200/25mg) combination ART by mouth for 6 months
HIV careother
HIV primary care (including Biktarvy delivery) will be conducted outside of a clinical setting by a community-based harm reduction program for 6 months.